Alivus Life Sciences Ltd

Incorporation of Brazil subsidiary

• Subsidiary named Alivus Life Sciences Do Brasil Ltda was incorporated in Sao Paulo, Brazil on Sep 15, 2026.
• Authorized capital is R$500,000; 100% of paid-up capital to be held by the parent.
• Consideration for the subscription is cash; subscription amount not exceeding R$500,000.
• 100% of the paid-up share capital will be held by Alivus Life Sciences Ltd.
• Initial subscription is not a related party transaction; no promoter group interest.
• Regulatory approval obtained from Brazil's National Registrar of Legal Entities.
• Turnover is not applicable as the entity is newly incorporated.
• Date of incorporation: September 15, 2026 (Brazil time 18:50).
• Industry: Pharmaceuticals.

Meeting Details

• Date: September 17, 2026; Time: not specified.
• Name/organiser: Kotak Healthcare Forum 2026.
• Mode: In-Person; Place: Mumbai.
• Type: Group/One-On-One.

Participants

• Key company participants: management representatives to attend.
• Company Secretary & Compliance Officer to attend.

Purpose

• Purpose: investor/analyst meeting at Kotak Healthcare Forum 2026.

Additional Notes

• Schedule may change due to exigencies on part of investor/analyst/company.

AGM details

• AGM held Sep 8, 2026 at 3:00 PM via VC/OAVM; record date 01 Sep 2026; concluded 4:40 PM.

Key resolutions

• Adopt Audited Financial Statements for the year ended 31 March 2026.
• Declare final dividend of Rs 5 per equity share for FY ended 31 March 2026.
• Re-appoint Hiren Patel as director, retiring by rotation.
• Ratify remuneration of Cost Auditor for the year ending 31 March 2027.

Voting results

• All four resolutions passed with requisite majority.

Dividend

• Final dividend of Rs 5 per equity share approved.

Director changes

• Hiren Patel reappointed as director; retiring by rotation.

Auditor appointments

• Remuneration of Cost Auditor for FY ending 31 March 2027 ratified.

Meeting Details

• Date: September 10, 2026; In-person in Mumbai; Group/One-on-One investor meetings with various MF/Institutions.

Meeting Details

• Aug 28, 2026 — Mirae Asset (US): Virtual, One-on-One investor meeting.
• Sept 1, 2026 — Emkay Global: In-person, Mumbai, One-on-One.
• Sept 1, 2026 — SIMPL: In-person, Mumbai, One-on-One.
• Sept 2, 2026 — Lyptus Capital: Virtual, One-on-One.

Participants

• Key company participant: Company Secretary & Compliance Officer.

Purpose

• Intimation of Investors/Analyst meetings with external investors and analysts.

Deal details

• Alivus Life Sciences to acquire 76% stake in IQGenX Pharma Private Limited for INR 91.2 million.

Deal timing

• Acquisition subject to customary closing conditions; expected to close by end of the current calendar year.

Strategic rationale

• Expands formulation development capabilities and global CDMO footprint with IQGenX platform.

Platform capabilities

• Bioequivalence and stability studies, pre-formulation, scale-up, regulatory submissions support.

Integration plan

• IQGenX to complement Alivus' oncology API portfolio and enable out-licensing across geographies.

Financials and ownership

• Total consideration INR 91.2 million for 76% stake.

Operational footprint

• IQGenX founded in October 2016; CRO working in regulated markets worldwide.

Regulatory readiness

• Alivus has four facilities with 1,424 KL installed capacity; inspected by USFDA, PMDA, EDQM.

Outlook

• Acquisition to broaden global customer base in the generic pharma segment.

Target & deal terms

• IQGEN-X Pharma Private Limited, Indian pharma company engaged in formulation development.
• Aggregate cash consideration INR 9.12 crore for 8,60,589 shares, 76% stake.
• Completion targeted by December 6, 2026, subject to conditions precedent.
• No promoter/group interest; acquisition not a related party transaction.

Strategic rationale

• Enables end-to-end API and CDMO solutions for customers.
• Strengthens Alivus' portfolio in pharmaceuticals.

Regulatory & timeline

• No government or regulatory approvals required.

Target background

• Incorporated Oct 2016; based in Navi Mumbai, India.
• Industry: Pharmaceuticals; focuses on formulation development.
• Products: formulation development for Oral Solids, Sterile Injectables, Ophthalmic solutions.
• Turnover history: 2023-24 Rs 267.5 Lacs; 2024-25 Rs 318.2 Lacs; 2025-26 Rs 348.0 Lacs.

Meeting Details

• Aug 18, 2026 — Green Lantern Capital — In-person, Mumbai — One-on-One
• Aug 18, 2026 — SIMPL — In-person, Mumbai — One-on-One
• Aug 19, 2026 — Burman Capital — Virtual — One-on-One
• Aug 19, 2026 — Karma Capital — In-person, Mumbai — One-on-One

Participants

• Company management to participate in all four one-on-one meetings

Purpose

• One-on-one investor/analyst discussions

Overview

• API manufacturer reporting on a standalone basis for FY2025-26.
• 90% of turnover derives from APIs with 75+ international markets.
• Exports represented 54.4% of turnover.

Key ESG Risks & Opportunities

• Talent recruitment, development, retention risk mitigated via structured programs and AI feedback.
• Supply chain disruption risk addressed through close supplier collaboration and monitoring.
• Counterfeit drugs risk mitigated by strict QC and robust traceability.
• Access to medicines opportunity via pricing strategies improving affordability.
• Carbon neutrality by 2030 and water neutrality by 2027 targeted.
• External assurance on Core KPIs adds credibility.

Governance & Policy Highlights

• Board oversight with a dedicated ESG Committee.
• Policies include anti-bribery, whistle-blower, human rights, Code of Conduct, Supplier Code.
• BSI provided limited assurance on Core KPIs for FY2025-26.
• Sept 30, 2025 Ankleshwar plant fire led to ₹29 lakh penalty; ₹10 lakh bank guarantee.
• Independent external assessments conducted by Dhir & Dhir Associates.

Social Responsibility & Workforce

• Total employees 2,284; permanent 2,272; workers 1,666; board female representation 14%.
• LTIFR: employees 2.01; workers 1.70; injuries 9 employees and 12 workers; 2 fatalities total.
• ISO 45001/ISO 14001; GMP ANVISA; 23,951 training hours for employee development.
• CSR programs Sampurna and ViGyasa benefited about 213k people; 35,000 trees planted.

Environmental Performance

• Total energy 827,183 GJ; renewables ~62% of energy use.
• GHG emissions: Scope 1 4,284.9 tCO2e; Scope 2 58,030.7 tCO2e; Scope 3 86,669 tCO2e (limited).
• Water withdrawal 367,994 KL; water consumption 342,188 KL; RO reuse and ETP/RO approach.
• Total waste 16,391 MT; major wastes include plastics 777.85 MT and ETP sludge 728.44 MT.

Stakeholder Engagement & Complaints

• Customers filed 47 complaints in FY2025-26; 8 pending at year-end.
• Investors filed 2 complaints; all resolved; formal channels include CX and RTA.
• Communities engaged via need assessments and CSR programs with baseline and impact studies.

Other Notable Metrics

• Life Cycle Assessment conducted for Azelaic Acid (3% of turnover) by Goldfinch Eng System.
• MSME input share 38%; 61% inputs sourced within India.
• Related party transactions: 2025-26 purchases 0%; sales 0.02% of total; 2024-25 sales 34.80%.
• Cybersecurity framework with IT Acceptable Usage Policy; no data breaches reported.